Critical analysis on the present methods for brain volume measurements in multiple sclerosis

Fragoso, Yára Dadalti; Willie, Paulo Roberto; Gonçalves, Marcus Vinícius Magno; Brooks, Joseph Bruno Bidin

doi:10.1590/0004-282x20170072

Cited by 7 publications

(5 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Axonal degeneration accumulates over the course of the disease and is the primary cause of sustained neurological disability in MS patients. The evaluation of axonal degeneration is still a major challenge in MS and it has been based mainly on MRI findings, particularly brain volume measures, which lack reproducibility [24][25][26][27] . The ability of optical coherence tomography to disclose neurodegeneration in MS has also been evaluated, but its use in clinical practice is still debatable 28 .…”

Section: Evaluation Of Neurodegenerationmentioning

confidence: 99%

Neurofilament light chain in the assessment of patients with multiple sclerosis

Domingues¹,

Fernandes²,

Leite³

et al. 2019

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an autoimmune, inflammatory, and degenerative disease of the central nervous system. Axonal degeneration is triggered by inflammation and is the pathological substrate of progressive disability in patients with MS. Therapeutic interventions can reduce inflammatory activity, thus delaying neurodegeneration and the progression of disability. Disease activity and neurodegeneration are assessed mainly through clinical evaluation and magnetic resonance imaging. These measures lack sensitivity and accuracy, so new biomarkers are necessary. Several markers have been studied and to date the most promising is neurofilament light (NfL), a component of the axonal cytoskeleton, which is released into cerebrospinal fluid (CSF) following axonal damage. In the present study, we review the current knowledge about CSF NfL determination in MS, clinically isolated syndrome, and radiologically isolated syndrome, and critically discuss how CSF NfL measurement may contribute to therapeutic decision-making in these patients.

show abstract

Section: Evaluation Of Neurodegenerationmentioning

confidence: 99%

Neurofilament light chain in the assessment of patients with multiple sclerosis

Domingues¹,

Fernandes²,

Leite³

et al. 2019

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…At the moment of writing this article, the estimation of total brain atrophy in MS patients is probably possible only after several years of longitudinal follow up [ 154 ]. It would seem cautious to say that makes it very difficult to use brain atrophy as a prognosis biomarker at individual level, especially in the early stages of the disease, when it would be most needed [ 76 , 155 , 156 , 157 ]. The same cannot be said regarding GM volumetrics.…”

Section: Resultsmentioning

confidence: 99%

Predictive MRI Biomarkers in MS—A Critical Review

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: In this critical review, we explore the potential use of MRI measurements as prognostic biomarkers in multiple sclerosis (MS) patients, for both conventional measurements and more novel techniques such as magnetization transfer, diffusion tensor, and proton spectroscopy MRI. Materials and Methods: All authors individually and comprehensively reviewed each of the aspects listed below in PubMed, Medline, and Google Scholar. Results: There are numerous MRI metrics that have been proven by clinical studies to hold important prognostic value for MS patients, most of which can be readily obtained from standard 1.5T MRI scans. Conclusions: While some of these parameters have passed the test of time and seem to be associated with a reliable predictive power, some are still better interpreted with caution. We hope this will serve as a reminder of how vast a resource we have on our hands in this versatile tool—it is up to us to make use of it.

show abstract

“…While volumetrics and their derived measurements have shown promise as prognosis biomarkers for MS, the estimation of total brain atrophy in MS patients is challenging and can only be achieved after several years of longitudinal follow-up [91]. Therefore, utilizing brain atrophy as a prognosis biomarker at an individual level, particularly in the early stages of the disease, is difficult [92][93][94][95]. Furthermore, spinal cord volumetrics, especially in the cervical segment, have been found to exhibit higher atrophy in MS patients than healthy controls.…”

Section: Plos Onementioning

confidence: 99%

Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies

Lomer,

Asalemi,

Saberi

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Introduction Multiple Sclerosis (MS) is a chronic neurodegenerative disorder that affects the central nervous system (CNS) and results in progressive clinical disability and cognitive decline. Currently, there are no specific imaging parameters available for the prediction of longitudinal disability in MS patients. Magnetic resonance imaging (MRI) has linked imaging anomalies to clinical and cognitive deficits in MS. In this study, we aimed to evaluate the effectiveness of MRI in predicting disability, clinical progression, and cognitive decline in MS. Methods In this study, according to PRISMA guidelines, we comprehensively searched the Web of Science, PubMed, and Embase databases to identify pertinent articles that employed conventional MRI in the context of Relapsing-Remitting and progressive forms of MS. Following a rigorous screening process, studies that met the predefined inclusion criteria were selected for data extraction and evaluated for potential sources of bias. Results A total of 3028 records were retrieved from database searching. After a rigorous screening, 53 records met the criteria and were included in this study. Lesions and alterations in CNS structures like white matter, gray matter, corpus callosum, thalamus, and spinal cord, may be used to anticipate disability progression. Several prognostic factors associated with the progression of MS, including presence of cortical lesions, changes in gray matter volume, whole brain atrophy, the corpus callosum index, alterations in thalamic volume, and lesions or alterations in cross-sectional area of the spinal cord. For cognitive impairment in MS patients, reliable predictors include cortical gray matter volume, brain atrophy, lesion characteristics (T2-lesion load, temporal, frontal, and cerebellar lesions), white matter lesion volume, thalamic volume, and corpus callosum density. Conclusion This study indicates that MRI can be used to predict the cognitive decline, disability progression, and disease progression in MS patients over time.

show abstract

Critical analysis on the present methods for brain volume measurements in multiple sclerosis

Cited by 7 publications

References 57 publications

Neurofilament light chain in the assessment of patients with multiple sclerosis

Neurofilament light chain in the assessment of patients with multiple sclerosis

Predictive MRI Biomarkers in MS—A Critical Review

Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies

Contact Info

Product

Resources

About